- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 1 - Immuno-Oncology Education Outreach Efforts
Surabhi Dangi-Garimella, PhD, managing editor of The American Journal of Managed Care's Evidence-Based series led the panel of experts in a discussion on immuno-oncology by first talking about checkpoint inhibitors currently in the market and under development.
Surabhi Dangi-Garimella, PhD, managing editor of The American Journal of Managed Care’s Evidence-Based series led the panel of experts in a discussion on immuno-oncology by first talking about checkpoint inhibitors currently in the market and under development.
Kimberly Shafer-Weaver, PhD, explained that in order to keep providers and patients more aware of the latest developments, there needs to be a better outreach effort at meetings and other venues to educate people about immunotherapists and how they can be used.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
